FOLFIRINOX Chemotherapy in Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis of Retrospective and Phase II Studies

LW Newsfeed
Metastatic pancreatic cancer remains one of the most lethal diseases with 5-year survival in the low single digits [1]. For several years since its introduction gemcitabine monotherapy was the standard palliative treatment for this disease. Gemcitabine was approved based on a combined benefit of symptom palliation and survival, though its survival prolongation benefit is modest at best. 
Read more . . .

image_printPrint Page